MA49452A - Procédé de prévention de thrombose de shunt de l'artère systémique-pulmonaire - Google Patents

Procédé de prévention de thrombose de shunt de l'artère systémique-pulmonaire

Info

Publication number
MA49452A
MA49452A MA049452A MA49452A MA49452A MA 49452 A MA49452 A MA 49452A MA 049452 A MA049452 A MA 049452A MA 49452 A MA49452 A MA 49452A MA 49452 A MA49452 A MA 49452A
Authority
MA
Morocco
Prior art keywords
systemic
pulmonary artery
shunt thrombosis
preventing shunt
preventing
Prior art date
Application number
MA049452A
Other languages
English (en)
Inventor
Thomas G Diacovo
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of MA49452A publication Critical patent/MA49452A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA049452A 2017-06-23 2018-06-22 Procédé de prévention de thrombose de shunt de l'artère systémique-pulmonaire MA49452A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762524102P 2017-06-23 2017-06-23

Publications (1)

Publication Number Publication Date
MA49452A true MA49452A (fr) 2021-05-05

Family

ID=62842064

Family Applications (1)

Application Number Title Priority Date Filing Date
MA049452A MA49452A (fr) 2017-06-23 2018-06-22 Procédé de prévention de thrombose de shunt de l'artère systémique-pulmonaire

Country Status (9)

Country Link
US (3) US11260071B2 (fr)
EP (1) EP3641784A1 (fr)
KR (1) KR20200018481A (fr)
CN (1) CN110740736A (fr)
BR (1) BR112019022676A2 (fr)
CA (1) CA3060345A1 (fr)
MA (1) MA49452A (fr)
MX (1) MX2019015448A (fr)
WO (1) WO2018234565A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA028885B1 (ru) * 2009-11-11 2018-01-31 Чиези Фармачеутичи С.П.А. Способы лечения или предотвращения тромбоза стента и инфаркта миокарда (варианты)

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US759316A (en) 1902-12-06 1904-05-10 Walter C Runge Telephone-receiver.
FR2530247B1 (fr) 1982-07-13 1986-05-16 Sanofi Sa Nouveaux derives de la thieno (3, 2-c) pyridine, leur procede de preparation et leur application therapeutique
US5196404B1 (en) 1989-08-18 1996-09-10 Biogen Inc Inhibitors of thrombin
FI101150B (fi) 1991-09-09 1998-04-30 Sankyo Co Menetelmä lääkeaineina käyttökelpoisten tetrahydrotienopyridiinin johd annaisten valmistamiseksi
AU679721B2 (en) 1993-02-10 1997-07-10 Astrazeneca Ab N-alkyl-2-substituted ATP analogues
ID21635A (id) 1996-12-20 1999-07-08 Astra Pharma Prod Komposisi farmasi untuk pengeringan beku
SE9702680D0 (sv) 1997-07-11 1997-07-11 Astra Pharma Prod New formulation
SE9904377D0 (sv) 1999-12-01 1999-12-01 Astra Pharma Prod Pharmaceutical combinations
ES2308633T3 (es) 2000-07-06 2008-12-01 Daiichi Sankyo Company, Limited Sal de adicion de maleato de derivados de la hidropiridina.
US7132408B2 (en) 2000-08-21 2006-11-07 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
US20020123791A1 (en) 2000-12-28 2002-09-05 Harrison William J. Stent design with increased vessel coverage
US6861424B2 (en) 2001-06-06 2005-03-01 Schering Aktiengesellschaft Platelet adenosine diphosphate receptor antagonists
US7758630B2 (en) 2003-04-14 2010-07-20 Tryton Medical, Inc. Helical ostium support for treating vascular bifurcations
US7749981B2 (en) 2003-10-21 2010-07-06 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with non-nucleotide P2Y12 receptor antagonist compound
US7335648B2 (en) 2003-10-21 2008-02-26 Inspire Pharmaceuticals, Inc. Non-nucleotide composition and method for inhibiting platelet aggregation
WO2005087266A1 (fr) 2004-03-05 2005-09-22 Vddi Pharmaceuticals Polytherapie bloquant l'agregation plaquettaire
EP1940399A2 (fr) 2005-08-19 2008-07-09 Eli Lilly & Company Utilisation des inhibiteurs de type par-1/par-4 pour le traitement de maladies vasculaires
DE102006020386A1 (de) 2006-04-28 2007-10-31 Dade Behring Marburg Gmbh Verfahren zur Bestimmung der Thrombozytenfunktion unter Flussbedingungen
WO2008006912A2 (fr) 2006-07-14 2008-01-17 Biocompatibles Uk Limited polymÈre
DE102006051625A1 (de) 2006-11-02 2008-05-08 Bayer Materialscience Ag Kombinationstherapie substituierter Oxazolidinone
KR101473207B1 (ko) 2007-04-13 2014-12-16 밀레니엄 파머슈티컬스 인코퍼레이티드 Ｘａ 인자 억제제로서 작용하는 화합물과의 병용 항응고 요법
KR20150041173A (ko) 2007-04-27 2015-04-15 사이덱스 파마슈티칼스, 인크. 클로피도그렐 및 설포알킬 에테르 사이클로덱스트린을 함유하는 제형 및 사용 방법
EP2079464A2 (fr) 2007-05-02 2009-07-22 Portola Pharmaceuticals, Inc. Dosage oral et intraveineux de l'inhibiteur p2y12 réversible et à action directe
US20090043380A1 (en) 2007-08-09 2009-02-12 Specialized Vascular Technologies, Inc. Coatings for promoting endothelization of medical devices
US8998978B2 (en) 2007-09-28 2015-04-07 Abbott Cardiovascular Systems Inc. Stent formed from bioerodible metal-bioceramic composite
WO2009070624A1 (fr) 2007-11-27 2009-06-04 The Trustees Of The University Of Pennsylvania Endoprothèse vasculaire
CA2623449C (fr) 2008-03-27 2010-11-02 Lance Baldo Nouvelle application de la bivalirudine dans le traitement d'un syndrome coronarien aigu
US9427448B2 (en) 2009-11-11 2016-08-30 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
US8680052B1 (en) * 2013-03-09 2014-03-25 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
US20130303477A1 (en) 2008-05-13 2013-11-14 The Medicines Company Maintenance of Platelet Inhibition During Antiplatelet Therapy
US8759316B2 (en) 2008-05-13 2014-06-24 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US20120141468A1 (en) 2008-05-13 2012-06-07 Lisa Ruderman Chen Maintenance of platelet inhibition during antiplatelet therapy
WO2009140092A1 (fr) * 2008-05-13 2009-11-19 The Medicines Company Conservation de l'inhibition de plaquettes durant une thérapie anti-plaquettes
KR101138294B1 (ko) 2008-09-24 2012-04-25 김형일 혈관벽 임시 골격용 생분해성 블랜드
US20120184504A1 (en) 2009-10-02 2012-07-19 Strony John T "The Use of a PAR-1 Antagonist in Combination with a P2Y12 ADP Receptor Antagonist for Inhibition of Thrombosis"
EA028885B1 (ru) 2009-11-11 2018-01-31 Чиези Фармачеутичи С.П.А. Способы лечения или предотвращения тромбоза стента и инфаркта миокарда (варианты)
US10376532B2 (en) 2009-11-11 2019-08-13 Chiesi Farmaceutici, S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
US20130040898A1 (en) 2010-04-29 2013-02-14 Pär Johansson Methods of treatment of patients at increased risk of development of ischemic events and compounds hereof
WO2012109406A1 (fr) * 2011-02-09 2012-08-16 The Medicines Company Méthodes de traitement de l'hypertension pulmonaire
CN103860459A (zh) 2012-12-11 2014-06-18 天津市汉康医药生物技术有限公司 一种坎格雷洛注射剂及其制备方法
CN106102750A (zh) * 2013-03-09 2016-11-09 凯西制药公司 治疗局部缺血事件、减少局部缺血事件的发生和/或预防局部缺血事件的方法
JPWO2016035780A1 (ja) 2014-09-02 2017-06-15 第一三共株式会社 ステント留置後の血栓・塞栓の形成を抑制するための医薬組成物
MA41326A (fr) 2015-01-14 2021-04-28 Chiesi Farm Spa Formulations pharmaceutiques comprenant du cangrelor de haute pureté et leurs procédés de préparation et d'utilisation

Also Published As

Publication number Publication date
US20200054662A1 (en) 2020-02-20
KR20200018481A (ko) 2020-02-19
MX2019015448A (es) 2020-02-19
WO2018234565A1 (fr) 2018-12-27
CN110740736A (zh) 2020-01-31
US20240342205A1 (en) 2024-10-17
RU2019142647A (ru) 2021-07-23
EP3641784A1 (fr) 2020-04-29
RU2019142647A3 (fr) 2021-11-29
BR112019022676A2 (pt) 2020-05-19
CA3060345A1 (fr) 2018-12-27
US20220117994A1 (en) 2022-04-21
US11260071B2 (en) 2022-03-01

Similar Documents

Publication Publication Date Title
MA52665A (fr) Procédé d'amélioration de l'expression de l'hémoglobine foetale
HUE063284T2 (hu) Eljárás vaszkuláris gyulladás megállapítására
MA46180A (fr) Analogues de l'amyline
MA50169A (fr) Procédé de production d'un électrocatalyseur
MA51337A (fr) Inhibiteurs spiro exo-aza de l'interaction ménine-mll
MA42423A (fr) Procédé de préparation d'un revêtement
HK1247615A1 (zh) 作為治療血栓形成的因子xia抑制劑的氧代吡啶衍生物
EP3894768C0 (fr) Procédés de cryo-durcisssement
DK3286317T3 (da) Dynamin 2-inhibitor til behandlingen af duchennes muskeldystrofi
GB201804594D0 (en) Bonegraft substituteand method of manufacture
IT201700093172A1 (it) Metodo per l'identificazione precoce di riacutizzazioni di broncopneumopatia cronica ostruttiva
IL281720A (en) HMGB1 protein derivatives to remove biofilms
DK3331610T3 (da) Midler til anvendelse til behandling af gliom
SG11202010677XA (en) Methods for the production of methacrylates
GB201805904D0 (en) Methods of Manufacture
MA49452A (fr) Procédé de prévention de thrombose de shunt de l'artère systémique-pulmonaire
DE112018004164A5 (de) Verfahren zur Wertbestimmung von Parametern
PL3642440T3 (pl) Profilowany element do wytwarzania ram
MA49555A (fr) Procédé amélioré de préparation d'imetelstat
GB201808575D0 (en) Methods for the treatment of psoriatic arthrits
MA43764A (fr) Inhibiteur monovalent de l'interaction hutnfr1
IL286857A (en) Methods for treating beta-thalassemia
SG11202105877YA (en) Method of treatment
PL3489218T3 (pl) Sposób wytwarzania fenyloaminohydroksyantrachinonów
PL3431656T3 (pl) Sposób obróbki kamieni tłuczniowych